UNSPSC 51171955: Roxatidine

This classification denotes an anti-ulcer agent and histamine h2 antagonist with the molecular formula C17H26N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IV9VHT3YUM, chemically known as acetamide, 2-hydroxy-n-(3-(3-(1-piperidinylmethyl)phenoxy)propyl)- but generally known as roxatidine, which bears US NIH Compound Identifier 91276. European Medicines Agency schedules Roxatidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10396MIG.

UNSPSC 51171955 Roxatidine is a Commodity code representing a specific pharmaceutical active ingredient used in acid-reflux and gastrointestinal treatments. State and local procurement activity under this code focuses on purchasing roxatidine as a component of broader pharmaceutical supply contracts, typically bundled within generic multi-source drug procurement programs serving correctional facilities, health systems, and state employee health plans. Issuing bodies include state health and human services departments, county corrections and community supervision agencies, and state-administered cooperative purchasing alliances that aggregate demand across multiple jurisdictions. The work involves pharmaceutical manufacturing and wholesale distribution compliance with FDA, SAMHSA, and state board of pharmacy certification requirements, including Good Manufacturing Practices (cGMP) and Drug Supply Chain Security Act (DSCSA) adherence.

Recent activity centers in Texas and Minnesota. The Collin County Community Supervision and Corrections Department issued RFP 2026-327 on July 9, 2026 (due July 23, 2026) for offender specimen collection and drug testing services with an estimated contract value of $600,000 over two years with three optional one-year renewals, though this opportunity addresses testing services rather than roxatidine supply itself. More directly aligned, the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities, including Oregon, with awarded vendors to be provided to authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) by May 15, 2026 and agreements effective July 1, 2026. The Texas Health and Human Services Commission also issued RFI No. HHS0017013 on April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription programs, signaling future procurement intent for pharmaceutical supply optimization. MMCAP's RFP weights price competitiveness at 75 percent and requires vendors to certify cGMP and DSCSA compliance, maintain relationships with at least two of three authorized wholesalers, and accept a 3 percent administrative fee.